Actimed Therapeutics

Executive Summary

Actimed Therapeutics is a UK-based biopharmaceutical company developing novel small molecule treatments for cachexia and other muscle wasting disorders, including cancer cachexia, muscle optimization in obesity, and ALS. Founded in 2014, the company addresses a significant unmet need in an underserved patient population, aiming to improve quality of life and reduce burden on patients and caregivers. While the company remains private with limited public financial details, its focused pipeline and targeted approach position it as a potential player in the muscle wasting therapeutics space. The lack of disclosed clinical stage or recent funding rounds suggests early to mid-stage development, which carries inherent risk but also upside if key milestones are achieved.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead cachexia candidate40% success
• Q4 2026Series A or B funding round to advance pipeline50% success
• Q4 2026Preclinical proof-of-concept data for ALS program30% success